By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

European Commission (EC) 

Rue Joseph II
Jozef II straat 70
Brussels    B-1000  Belgium
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Medical Device






Company News
Swedish Orphan Biovitrum Release: European Commission (EC) Approves Orfadin Oral Suspension 6/29/2015 10:32:52 AM
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) 6/29/2015 7:36:35 AM
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Oculopharyngeal Muscular Dystrophy 6/25/2015 6:35:31 AM
European Commission (EC) Approves Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab), The First And Only PD-1 Checkpoint Inhibitor Approved In Europe, For Both First-Line And Previously-Treated Advanced Melanoma Patients 6/19/2015 8:02:06 AM
The European Commission (EC) Approves Helsinn's Akynzeo (netupitant/palonosetron) for the Prevention Of Chemotherapy Induced Nausea And Vomiting (CINV) In The European Union 6/2/2015 6:27:03 AM
PRANA Biotechnology (PRAN) Release: European Commission (EC) Approves PBT2 Orphan Designation For Huntington’s Disease 6/1/2015 11:30:27 AM
Helsinn Group Release: The European Commission (EC) Approves ALOXI (palonosetron HCl) Injection To Prevent Nausea And Vomiting Due To Chemotherapy In Children As Young As One Month 5/27/2015 6:44:54 AM
European Commission (EC) Approves Amgen (AMGN)'s Vectibix (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer 4/6/2015 6:34:05 AM
The Medicines Company (MDCO) Receives European Commission (EC) Approval For Three Hospital Acute Care Products: KENGREXAL (Cangrelor), ORBACTIV (Oritavancin) And RAPLIXA(Sealant Powder) 3/30/2015 12:41:14 PM
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015 6:43:15 AM
123456789
//-->